Abstract:Foot-and-mouth disease (FMD) is one of the most economically and socially devastating diseases affecting animal agriculture throughout the world. Although mortality is usually low in adult animals, millions of animals have been killed in efforts to rapidly control and eradicate FMD. The causing virus, FMD virus (FMDV), is a highly variable RNA virus occurring in seven serotypes (A, O, C, Asia 1, Sat 1, Sat 2 and Sat 3) and a large number of subtypes. FMDV is one of the most infectious agents known, affecting cloven-hoofed animals with significant variations in infectivity and virus transmission. Although inactivated FMD vaccines have been available for decades, there is little or no cross-protection across serotypes and subtypes, requiring vaccines that are matched to circulating field strains. Current inactivated vaccines require growth of virulent virus, posing a threat of escape from manufacturing sites, have limited shelf life and require re-vaccination every 4-12 months. These vaccines have aided in the eradication of FMD from Europe and the control of clinical disease in many parts of the world, albeit at a very high cost. However, FMDV persists in endemic regions impacting millions of people dependent on livestock for food and their livelihood. Usually associated with developing countries that lack the resources to control it, FMD is a global problem and the World Organization for Animal Health and the United Nations' Food Agriculture Organization have called for its global control and eradication. One of the main limitations to FMDV eradication is the lack of vaccines designed for this purpose, vaccines that not only protect against clinical signs but that can actually prevent infection and effectively interrupt the natural transmission cycle. These vaccines should be safely and inexpensively produced, be easy to deliver, and also be capable of inducing lifelong immunity against multiple serotypes and subtypes. Furthermore, there is a need for better integrated strategies that fit the specific needs of endemic regions. Availability of these critical components will greatly enhance the chances for the global control and eradication of FMDV.

Advances on Antiviral Approach of Foot-and-Mouth Disease

Development of Foot-and-Mouth Disease Vaccines in Recent Years

Development of vaccines toward the global control and eradication of foot-and-mouth disease

Advances in the Diagnosis of Foot-and-Mouth Disease

Developing Vaccines Against Foot-and-Mouth Disease: a Biotechnological Approach

Clinical Evaluation of Immune Effect of FMD Vaccine

Inhibition of Foot and Mouth Disease Virus Replication in Vitro and in Vivo by Dual Short Hairpin RNA-Mediated RNA Interference

Adenovirus-mediated RNA interference against foot-and-mouth disease virus infection both in vitro and in vivo.

The Pathogenesis of Foot-and-Mouth Disease Virus Infection: How the Virus Escapes from Immune Recognition and Elimination

Advances in Reverse Genetics-Based Vaccines of Foot and Mouth Disease

Virus–Host Interactions in Foot-and-Mouth Disease Virus Infection

Foot-and-mouth disease virus: Prospects for using knowledge of virus biology to improve control of this continuing global threat

Preventive effects of quercetin against foot-and-mouth disease virus in vitro and in vivo by inducing type I interferon

Advance in Foot-and-mouth Disease Virus Infectious Cycle

Virulence and Immune Evasion Strategies of FMDV: Implications for Vaccine Design

Global Foot-and-Mouth Disease Research Update and Gap Analysis: 5 - Biotherapeutics and Disinfectants

The Proposed Strategic Plan to Limit The Spread of Foot-and-Mouth Disease

Enhancement of Serological Immune Responses to Foot-And-Mouth Disease Vaccine by A Supplement Made of Extract of Cochinchina Momordica Seeds

Towards improvements in foot-and-mouth disease vaccine performance

A Novel Mucosal Vaccine Against Foot-and-Mouth Disease Virus Induces Protection in Mice and Swine

Immune Enhancing Effects of Recombinant Bovine IL-18 on Foot-and-mouth Disease Vaccination in Mice Model